Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma

NCT03682796 is registered in ClinicalTrials.gov with Triphase Research and Development III Corp. as lead sponsor.

NCT NCT03682796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03682796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Lead sponsor
Triphase Research and Development III Corp.
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2018
Completion date
November 17, 2021
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, lymphoma, b-cell, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, mantle-cell, lymphoma, marginal zone, lymphoma, non-hodgkin